Logo

Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics

Share this
Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics

Janssen Enters into a License and Collaboration Agreement with F-star to Develop and Commercialize Multiple Bispecific Antibody Therapeutics

Shots:

  • F-star to receive $17.5M up front and is eligible to receive ~$1.35B as near-term fees & milestones along with royalties on net sales of the product
  • Janssen to get an exclusive royalty-bearing license globally to research- develop & commercialize up to 5 novels bispecific Abs directed to Janssen therapeutic targets using F-star’s Fcab and mAb2 platforms & will lead all research- development- and commercialization activities
  • F-star's platform allows changes in the Fc region of a natural Ab to generate 2 additional distinct Ag binding sites. Fcab building blocks can be inserted into a natural IgG Ab to develop tetravalent mAb2 bispecific Abs that bind to two different Ag

Click here to­ read full press release/ article | Ref: F-star | Image: Prnewswire


Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family